Suppr超能文献

肝素与枸橼酸盐用于接受持续肾脏替代治疗的危重症患者抗凝的比较

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy.

作者信息

Tillman Joanne

机构信息

Intensive Care Unit, Guys and St Thomas' NHS Foundation Trust, London, UK.

出版信息

Nurs Crit Care. 2009 Jul-Aug;14(4):191-9. doi: 10.1111/j.1478-5153.2009.00339.x.

Abstract

BACKGROUND

Continuous renal replacement therapy (CRRT) is commonly used in the care of critically ill patients (Gabutti et al., 2002). Critical illness increases the likelihood to both coagulation and bleeding, making anticoagulation for CRRT problematic.

AIMS

This mini-review aims to examine the evidence that compares the use of systemic heparin and regional citrate as forms of anticoagulation for CRRT in critically ill patients. The primary outcome of interest was haemofilter circuit survival, and the secondary outcome was reduced risk of bleeding.

SEARCH STRATEGY

A systematic literature search was undertaken to identify all studies comparing these drugs. The Cochrane Library, Medline and Embase databases were searched. Eighty-nine articles were found. Included studies were randomized controlled trials (RCTs), which used a target population of critically ill adults. Studies were excluded if they had not been written in English and if they were not available through King's College London. After applying the inclusion and exclusion criteria, three RCTs comparing the use of systemic heparin and regional citrate were included in the review.

RESULTS

Two studies showed significant differences in circuit survival time, with citrate prolonging survival time. All studies showed an increased risk of bleeding in the heparin group, resulting in a higher rate of transfusion while heparin was being used.

CONCLUSIONS

The studies examined lacked reference to the power of the studies and strength in the presentation of the results. Because of the lack of reliability in the studies, it would be suggested that further research is needed on this topic in order to produce rigorous high-quality reviews with limited bias. The use of citrate, as with all treatments in clinical practice, should be used with caution and assessed on an individual patient basis. Reviewing this evidence helps to gain an insight into different treatment options available, identifying some of the risks and benefits.

摘要

背景

连续性肾脏替代治疗(CRRT)常用于危重症患者的护理(加布蒂等人,2002年)。危重症会增加凝血和出血的可能性,这使得CRRT的抗凝治疗存在问题。

目的

本综述旨在研究比较全身肝素和局部枸橼酸盐作为危重症患者CRRT抗凝形式的证据。主要关注的结果是血液滤过回路的存活时间,次要结果是出血风险降低。

检索策略

进行了系统的文献检索,以识别所有比较这些药物的研究。检索了Cochrane图书馆、Medline和Embase数据库。共找到89篇文章。纳入的研究为随机对照试验(RCT),目标人群为成年危重症患者。如果研究不是用英文撰写的,或者无法通过伦敦国王学院获取,则将其排除。应用纳入和排除标准后,本综述纳入了三项比较全身肝素和局部枸橼酸盐使用情况的RCT。

结果

两项研究显示回路存活时间存在显著差异,枸橼酸盐可延长存活时间。所有研究均显示肝素组出血风险增加,导致使用肝素期间输血率更高。

结论

所审查的研究缺乏对研究效力和结果呈现力度的参考。由于这些研究缺乏可靠性,建议对该主题进行进一步研究,以产生偏差有限的严谨高质量综述。与临床实践中的所有治疗方法一样,枸橼酸盐的使用应谨慎,并根据个体患者情况进行评估。审查这些证据有助于深入了解可用的不同治疗选择,识别一些风险和益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验